TRT, hormonal acne, and cardiovascular risk: separating signal from noise

What did @coach.neek actually say?

The creator summarized findings from what appears to be the TRAVERSE trial, noting that men on testosterone replacement had roughly 7% cardiovascular event rates, comparable to placebo. He then spent most of the video warning viewers not to misuse that finding. His core message: "this is not a sign that you've got a whole pass, a free pass to just do whatever the hell you want." That's a reasonable framing. He correctly identified that the study involved older, hypogonadal men with pre-existing cardiovascular disease, not young healthy men chasing optimization. The warning about extrapolating trial data to a different population is genuinely good public health messaging, and it doesn't get said enough in this corner of TikTok.

Does the science back this up?

Mostly, yes. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) was a randomized, placebo-controlled trial of about 5,200 men aged 45-80 with hypogonadism and elevated cardiovascular risk. The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke. At roughly 22 months median follow-up, the event rate was 7.0% in the testosterone group versus 7.3% in the placebo group. Non-inferiority was established. That matches what the creator described. What the trial also found, and what the creator did not mention, is a statistically significant increase in atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm. Those aren't minor footnotes. They matter clinically, especially for bodybuilders already stressing the cardiovascular system with supraphysiologic use, which this trial had nothing to do with.

What did they get wrong (or right)?

He got the headline right and the caveat right. Credit where it's due. But there are a few gaps worth naming.

• He called the study only 2 years long, which is roughly accurate, median follow-up was about 22 months, though some participants were followed longer.
• He did not mention the atrial fibrillation signal. The TRAVERSE trial found a significantly higher rate of AFib in the testosterone group (HR approximately 1.35). For someone telling viewers to manage their blood pressure and cholesterol, leaving out AFib is a real omission.
• His term "hypergonatolist" appears to be a mispronunciation of "hypogonadal," which is the opposite hormonal state. Hypogonadism means low testosterone, not high. Small error, but worth clarifying for an audience that may not know the difference.
• His advice to monitor "mean cell volumes" and "cell distribution" is oddly specific and not standard TRT monitoring guidance. Hematocrit and hemoglobin are the relevant red blood cell markers in TRT management, not MCV or RDW in isolation.

What should you actually know?

The TRAVERSE trial is genuinely reassuring for its target population: men over 45 with confirmed hypogonadism and existing cardiovascular risk factors, using testosterone to restore physiologic levels. It is not a study of young men, supraphysiologic dosing, or bodybuilding-context testosterone use. The creator is right to say so. What the study cannot tell you is whether long-term use beyond two years is safe, what happens at doses above replacement range, or what the risk profile looks like in men without pre-existing disease. It also cannot speak to the combination of testosterone with other compounds, which is common in the populations this kind of content actually reaches. The creator's advice to manage cholesterol, blood pressure, and overall cardiovascular health is correct. He should have added: get an ECG periodically, because atrial fibrillation is now a documented concern in this literature, and it's often asymptomatic until it isn't.